drug_type
RELEVANT_DRUG
intervention_type
Autologous cellular immunotherapy
drug_description
Autologous peripheral blood mononuclear cells (primarily T cells) activated ex vivo with IL-2 and OKT3 and coated with OKT3 and elotuzumab to generate bispecific antibody–armed T cells targeting SLAMF7+ multiple myeloma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Peripheral Blood Mononuclear Cells
drug_category
OTHER ENGINEERED IMMUNE CELL
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous PBMCs (primarily T cells) are activated ex vivo with IL-2/OKT3 and coated with OKT3 (anti‑CD3) plus elotuzumab (anti‑SLAMF7), creating bispecific antibody–armed T cells that bridge CD3 on T cells to SLAMF7 on myeloma cells, forming an immune synapse and redirecting T‑cell cytotoxicity against SLAMF7+ multiple myeloma.
drug_name
SLAMF7 FPBMC
nct_id_drug_ref
NCT04864522